MEDICARE PART D COST SHARING AND SPECIALTY DRUG INITIATION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS

被引：0
|
作者：
Doshi, J. A. [1 ]
Li, P. [1 ]
Huo, H. [1 ]
Pettit, A. R. [1 ]
Kumar, R. [1 ]
Huntington, S. F. [2 ]
Weiss, B. M. [3 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Yale Univ, New Haven, CT USA
[3] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.035
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
ME2
引用
收藏
页码：A3 / A3
页数：1
相关论文
共 50 条
  • [31] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
    Saglio, Giuseppe
    Kim, Dong-Wook
    Issaragrisil, Surapol
    le Coutre, Philipp
    Etienne, Gabriel
    Lobo, Clarisse
    Pasquini, Ricardo
    Clark, Richard E.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Gallagher, Neil
    Hoenekopp, Albert
    Dong, Mei
    Haque, Ariful
    Larson, Richard A.
    Kantarjian, Hagop M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2251 - 2259
  • [32] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [33] Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase
    Deotare, Uday
    Kim, Dennis Dong Hwan
    Lipton, Jeffrey H.
    DRUGS & AGING, 2016, 33 (05) : 335 - 345
  • [34] Multicenter experience with imatinib, mesylate in newly diagnosed chronic myeloid leukemia (CML) patients
    Carella, A. M.
    Lerma, E.
    Orlandi, E.
    Lazzarino, M.
    Annunziata, M.
    Ferrara, F.
    Pungolino, E.
    Morra, E.
    Miglino, M.
    Gobbi, M.
    BLOOD, 2007, 110 (11) : 210B - 210B
  • [35] Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
    Dusetzina, Stacie B.
    Winn, Aaron N.
    Abel, Gregory A.
    Huskamp, Haiden A.
    Keating, Nancy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) : 306 - 311
  • [36] The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients
    Park, Hyunkyung
    Kang, Sungbong
    Kim, Inho
    Kim, Sangsoo
    Kim, Hyeong-Joon
    Shin, Dong-Yeop
    Kim, Dae-Young
    Lee, Kyoo-Hyung
    Ahn, Jae-Sook
    Sohn, Sang-Kyun
    Lee, Jeong-Ok
    Cheong, June-Won
    Kim, Hoon-Gu
    Kim, Hawk
    Nam, Seung-Hyun
    Park, Sang-Gon
    Park, Seonyang
    Kim, Kyoung Ha
    Lee, Yoo Jin
    Do, Young Rok
    Park, Seong Kyu
    Song, Hun Ho
    Jung, Chul Won
    LEUKEMIA RESEARCH, 2022, 114
  • [37] Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase
    Uday Deotare
    Dennis Dong Hwan Kim
    Jeffrey H. Lipton
    Drugs & Aging, 2016, 33 : 335 - 345
  • [38] CHRONIC MYELOID LEUKEMIA: IS THE REAL PROGNOSIS OF NEWLY DIAGNOSED PATIENTS REALLY SO GOOD?
    Zackova, D.
    Racil, Z.
    Janousova, E.
    Dvorakova, D.
    Jurcek, T.
    Minarik, R.
    Prochazkova, J.
    Oltova, A.
    Weinbergerova, B.
    Semerad, L.
    Pavlovska, L.
    Dusek, L.
    Mayer, J.
    HAEMATOLOGICA, 2015, 100 : 445 - 445
  • [39] Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients
    Asmaa M. Zahran
    Hosny Badrawy
    Abeer Ibrahim
    International Journal of Clinical Oncology, 2014, 19 : 753 - 760
  • [40] Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients
    Zahran, Asmaa M.
    Badrawy, Hosny
    Ibrahim, Abeer
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 753 - 760
12345